Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Over the last 12 months, insiders at Aytu BioPharma, Inc. have bought $0 and sold $0 worth of Aytu BioPharma, Inc. stock.
On average, over the past 5 years, insiders at Aytu BioPharma, Inc. have bought $2.07M and sold $40.64M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 12,000 shares for transaction amount of $22,428 was made by PYSZCZYMUKA GREG (Chief Commerical Officer) on 2023‑06‑16.
2023-06-16 | Chief Commerical Officer | 12,000 0.3307% | $1.87 | $22,428 | +53.30% | |||
2023-06-14 | Chief Executive Officer | 14,000 0.3999% | $1.86 | $26,079 | +58.66% | |||
2022-12-19 | Chief Executive Officer | 112,371 0.1842% | $0.22 | $25,048 | -47.51% | |||
2022-12-19 | Chief Commercial Officer | 100,000 0.18% | $0.24 | $24,480 | -47.51% | |||
2022-11-18 | Chief Executive Officer | 222,000 0.3705% | $0.24 | $52,614 | -49.58% | |||
2022-11-18 | Chief Financial Officer | 90,000 0.1458% | $0.23 | $20,700 | -49.58% | |||
2020-12-11 | director | 1.33M 9.5911% | $6.00 | $8M | -17.04% | |||
2020-04-27 | Sale | director | 5.11M 4.0608% | $1.82 | $9.3M | -49.75% | ||
2020-04-15 | Sale | 10 percent owner | 92,777 0.082% | $1.55 | $144,092 | -33.23% | ||
2020-03-10 | Sale | director | 22.03M 43.1464% | $1.42 | $31.2M | -41.46% | ||
2019-12-20 | 26,000 0.1525% | $0.88 | $22,880 | +39.53% | ||||
2019-12-19 | 52,788 0.3082% | $0.85 | $44,870 | +44.58% | ||||
2019-12-19 | 55,000 0.3354% | $0.89 | $48,824 | +44.58% | ||||
2018-12-21 | Sale | Chief Financial Officer | 3,330 0.053% | $0.81 | $2,711 | +74.68% | ||
2018-03-06 | Chief Executive Officer | 226,105 2.044% | $0.45 | $101,747 | -49.76% | |||
2018-03-06 | Chief Operating Officer | 226,105 2.044% | $0.45 | $101,747 | -49.76% | |||
2018-03-06 | Chief Financial Officer | 66,600 0.6021% | $0.45 | $29,970 | -49.76% | |||
2016-11-02 | Chief Executive Officer | 333,332 4.4318% | $1.68 | $559,998 | -80.47% | |||
2016-11-02 | Chief Operating Officer | 333,332 4.4318% | $1.68 | $559,998 | -80.47% | |||
2016-11-02 | Chief Financial Officer | 133,332 1.7727% | $1.68 | $223,998 | -80.47% |
Cerecor Inc. | 10 percent owner | 9713068 157.9522% | $1.58 | 0 | 1 | |
DOCKERY CARL | director | 5047591 82.0831% | $1.58 | 1 | 0 | |
ARMISTICE CAPITAL, LLC | director | 1333334 21.6824% | $1.58 | 3 | 2 | +22.36% |
Disbrow Jarrett | Chief Operating Officer | 439490 7.1469% | $1.58 | 4 | 0 | |
Gould Gregory A | Chief Financial Officer | 273565 4.4487% | $1.58 | 1 | 0 | |
Green David A | Chief Financial Officer | 266250 4.3297% | $1.58 | 1 | 1 | |
Oki Mark K | Chief Financial Officer | 190000 3.0897% | $1.58 | 1 | 0 | <0.0001% |
Cantrell Gary | director | 98333 1.5991% | $1.58 | 1 | 0 | |
Disbrow Joshua R. | Chief Executive Officer | 71591 1.1642% | $1.58 | 8 | 0 | +1.54% |
PYSZCZYMUKA GREG | Chief Commerical Officer | 21935 0.3567% | $1.58 | 2 | 0 | +2.89% |
Nantahala Capital Management Llc | $3.3M | 18.2 | 1.09M | 0% | +$0 | 0.15 | |
Stonepine Capital Management Llc | $1.44M | 7.91 | 472,469 | 0% | +$0 | 0.09 | |
Renaissance Technologies | $217,000.00 | 1.19 | 71,323 | +3.48% | +$7,301.99 | <0.0001 | |
Geode Capital Management | $105,109.00 | 0.58 | 34,563 | +4.59% | +$4,613.32 | <0.0001 | |
The Vanguard Group | $84,780.00 | 0.47 | 27,888 | +2.34% | +$1,936.49 | <0.0001 | |
BlackRock | $69,291.00 | 0.38 | 22,793 | 0% | +$0 | <0.0001 | |
Dimensional Fund Advisors | $46,329.00 | 0.26 | 15,240 | New | +$46,329.00 | <0.0001 | |
Acadian Asset Management | $44,000.00 | 0.25 | 14,622 | 0% | +$0 | <0.0001 | |
Northern Trust | $44,275.00 | 0.24 | 14,564 | -0.03% | -$12.16 | <0.0001 | |
Goldman Sachs | $42,201.00 | 0.23 | 13,882 | 0% | +$0 | <0.0001 | |
Citadel Advisors LLC | $37,012.00 | 0.2 | 12,175 | New | +$37,012.00 | <0.0001 | |
Tower Research Capital | $9,199.00 | 0.05 | 3,026 | +32.55% | +$2,258.71 | <0.0001 | |
Royal Bank of Canada | $8,000.00 | 0.05 | 2,709 | -24.73% | -$2,628.28 | <0.0001 | |
Morgan Stanley | $3,222.00 | 0.02 | 1,060 | -24.29% | -$1,033.47 | <0.0001 | |
UBS | $3,119.00 | 0.02 | 1,026 | +294.62% | +$2,328.61 | <0.0001 | |
JPMorgan Chase | $1,885.00 | 0.01 | 620 | -90.93% | -$18,895.60 | <0.0001 | |
Advisor Group Holdings Inc | $912.00 | 0.01 | 300 | 0% | +$0 | <0.0001 | |
Wells Fargo | $498.00 | <0.01 | 164 | -4.09% | -$21.26 | <0.0001 | |
Cibc Private Wealth Group Llc | $248.00 | <0.01 | 83 | New | +$248.00 | <0.0001 | |
Group One Trading | $112.00 | <0.01 | 37 | 0% | +$0 | <0.0001 | |
Bank of America | $152.00 | <0.01 | 50 | New | +$152.00 | <0.0001 | |
Huntington National Bank | $61.00 | <0.01 | 20 | New | +$61.00 | <0.0001 | |
Tsfg Llc | $0 | <0.01 | 1 | 0% | +$0 | <0.0001 | |
Fidelity Investments | $6.00 | <0.01 | 2 | +100% | +$3.00 | <0.0001 | |
CarsonAllaria Wealth Management | $15.00 | <0.01 | 5 | 0% | +$0 | <0.0001 | |
West Financial Advisors LLC | $31.00 | <0.01 | 10 | New | +$31.00 | <0.0001 | |
Newedge Advisors Llc | $64.00 | <0.01 | 21 | 0% | +$0 | <0.0001 |